[8-K] IN8BIO, INC. Reports Material Event

Rhea-AI Filing Summary

IN8bio, Inc. (INAB) filed an 8-K announcing new preclinical data from its gamma delta T cell engager program, INB-619. The company said the data will be presented at the 2025 American College of Rheumatology (ACR) Convergence Meeting in Chicago.

A company press release with additional details is attached as Exhibit 99.1 and incorporated by reference. This filing does not include financial results or transaction terms; it primarily serves to notify investors of the scientific presentation and provide the related press release.

false 0001740279 0001740279 2025-10-27 2025-10-27

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 27, 2025

IN8bio, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware		001-39692		82-5462585
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

350 5th Avenue, Suite 5330
New York, New York		10118
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: (646) 600-6438

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value per share		INAB		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On October 27, 2025, IN8bio, Inc. (the “Company”) issued a press release announcing the presentation of new preclinical data from its gd T cell engager (gd-TCE) program, INB-619, at the 2025 American College of Rheumatology (ACR) Convergence Meeting in Chicago. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Press Release, dated October 27, 2025
101		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

				IN8bio, Inc.
Date: October 27, 2025				By:		/s/ Patrick McCall
						Patrick McCall
						Chief Financial Officer and Secretary
						(Principal Financial and Accounting Officer)